Communication on Zofran™ (ondansetron) and dose-dependent QT interval prolongation – updated information on dosage and administration for intravenous use in elderly

GlaxoSmithKline would like to inform healthcare professionals of the updated dosage and administration information for intravenous (IV) Zofran™ in the management of chemotherapy and radiotherapy induced nausea and vomiting (CINV and RINV) in the elderly. This update follows a previous safety communication informing healthcare professionals of dose-dependent QT prolongation associated with IV Zofran™ and the new dose restrictions for this product. Further analysis of the results of this study demonstrated a concentration-dependent relationship which warrants specific guidance to be put in place for repeat IV Zofran™ dosing and for the use of IV Zofran™ in elderly patients. The package insert for Zofran™ has been updated to reflect the new safety information. Please refer to the letter for more details.

 
 
Healthcare professional, Therapeutic Products
Published:

Dear Healthcare Professional Letters

12 Dec 2019

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.moh.gov.sg/hpp/, and follow the procedures below to access the MOH Alert system.

Step 1: On the top navigation ribbon of webpage, select 'For Healthcare Professionals' followed by 'Health Professionals Portal' and click on the choice of profession. User will be redirected to the specific HPP webpage for the selected profession.

Step 2: Click on the Restricted Content icon on the left panel of webpage and login via SingPass.

Step 3: Click on the MOH Alert icon under ‘Applications’ section

Step 4: Click on the Drug Alert tab to view the DHCPLs.